SCHEMBL708207

SCHEMBL708207

C(C=Cc1ccccn1)=Cc1cnc2ccccc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.61
PDGFRA P16234 2/20 0.61
RAB9A P51151 7/20 0.54
KMT2A Q03164 5/20 0.49
KDM4E B2RXH2 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 5/20 0.46
MEN1 O00255 4/20 0.46
ATM Q13315 2/20 0.46
CYP1A2 P05177 1/20 0.42
ALDH1A1 P00352 4/20 0.41
MAPT P10636 3/20 0.41
GAA P10253 2/20 0.41
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
POLB P06746 1/20 0.40
CYP2A6 P11509 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL708206 1.00 PDGFRB (0.61) PDGFRBPDGFRARAB9AKMT2AKDM4E
SCHEMBL709038 0.90 PDGFRB (0.70) PDGFRBPDGFRARAB9AKMT2AKDM4E
SCHEMBL709039 0.90 PDGFRB (0.70) PDGFRBPDGFRARAB9AKMT2AKDM4E
SCHEMBL709276 0.84 NPC1 (0.59) RAB9AKMT2AKDM4ESMN1; SMN2NPC1
SCHEMBL709275 0.84 NPC1 (0.59) RAB9AKMT2AKDM4ESMN1; SMN2NPC1
SCHEMBL6228936 0.83 PDGFRB (0.63) PDGFRBPDGFRARAB9AKMT2AKDM4E
SCHEMBL6228938 0.83 PDGFRB (0.63) PDGFRBPDGFRARAB9AKMT2AKDM4E
SCHEMBL6228934 0.83 PDGFRB (0.63) PDGFRBPDGFRARAB9AKMT2AKDM4E
SCHEMBL17461325 0.82 PDGFRB (0.67) PDGFRBPDGFRARAB9AKMT2AKDM4E
SCHEMBL31014180 0.82 PDGFRB (0.67) PDGFRBPDGFRARAB9AKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20040242615-A1 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242615-A1 Utilities of olefin derivatives APOL1, NR1H2, APOB PDGFRB 2744/4885PDGFRA 3181/4885RAB9A 4723/4885
US-20090036457-A1 Utilities of olefin derivatives APOL1, APOB, NR1H2 PDGFRB 3680/4885PDGFRA 4261/4885RAB9A 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.